Setting New Benchmarks for Antibody Analysis - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Setting New Benchmarks for Antibody Analysis

Tosoh Bioscience expands the renowned TSKgel SW series of aqueous size exclusion HPLC columns by three new UHPLC columns, tailored to different aspects of antibody analysis.

Aqueous SEC on silica based stationary phases is state of the art for aggregation analysis. TSKgel G3000SWXL is regarded as the gold standard of antibody SEC columns. In an ongoing approach to adopt stationary phases to the user’s needs, the proven surface chemistry of the TSKgel SW series was used to developed new UHPLC columns.

TSKgel SuperSW mAb HTP – ‘HTP’ for high throughput – was developed to enable easy transfer of HPLC methods based on TSKgel SWXL to fast UHPLC analysis. Small particle size silica beads featuring the same pore size and coating as G3000SWXL are packed in UHPLC column hardware with 4.6 mm inner diameter. This allows for doubling the throughput without compromising resolution between monomer and dimer. Another approach was used in the development of TSKgel SuperSW mAb HR – ‘HR’ indicating high resolution. The SuperSW stationary phase was packed in columns featuring the traditional dimensions for HPLC gel filtration columns of 7.8 mm ID and 30 cm length. This results in superior resolution between fragments, monomers, and aggregates. TSKgel UltraSW Aggregate covers the range of higher molecular weights and provides very good separation of antibody dimers and higher aggregates. It is based on even smaller silica beads with slightly larger pore size.

The new columns are ideally used in UHPLC instruments, even though the columns will not create back pressures exceeding the pressure limits of standard HPLC systems.

TOSOH BIOSCIENCE GmbH
Zettachring 6
70567 Stuttgart, Germany
Tel.   +49 (0)711 13257-0
info.tbg@tosoh.com
www.separations.eu.tosohbioscience.com

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
26%
Attracting a skilled workforce
29%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
31%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans
FindPharma Custom Search

Click here